TWST Stock Risk & Deep Value Analysis
Twist Bioscience Corp
Healthcare • Diagnostics & Research
DVR Score
out of 10
The Bottom Line on TWST
We analyzed Twist Bioscience Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TWST through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
TWST Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
About Twist Bioscience Corp (TWST)
Sector
Healthcare
Industry
Diagnostics & Research
Market Cap Category
mid
Market Cap
$1.98B
TWST Deep Value Analysis
TWST Red Flags & Warning Signs
- âš
Lower-than-expected revenue growth or higher-than-expected cash burn in earnings reports
- âš
Emergence of a superior or more cost-effective DNA synthesis technology from competitors
- âš
Regulatory hurdles or delays impacting synthetic biology applications or DNA data storage
Unlock TWST Red Flags & Risk Warnings
Create a free account to see the full analysis
TWST Financial Health Metrics
Market Cap
$1.98B
TWST Competitive Moat Analysis
Sign in to unlockMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Twist's moat is built on its proprietary silicon-based synthesis platform, offering superior throughput and cost-efficiency. This technological lead, protected by strong IP, makes replication difficult and expensive. As customers integrate Twist's highly customized products into their workflows, switching costs increase, further entrenching its position. Continued innovation and scaling will strengthen this moat over time.
TWST Competitive Moat Analysis
Sign up to see competitive advantages
TWST Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early February 2026)
- •Expanded commercial agreements or new partnerships in drug discovery
- •Updates on new product pipelines or services (e.g., new oligo pools, synthetic genes)
Medium-Term (6-18 months)
- •Major advancements or pilot programs in DNA data storage with key partners
- •Increased adoption of Twist's synthetic DNA across industrial biotech applications
- •Demonstrated improvements in gross margins and reduced cash burn
Long-Term (18+ months)
- •Establishment as the dominant platform provider for synthetic biology R&D and manufacturing
- •Commercialization and significant revenue generation from DNA data storage solutions
- •Disruption of traditional chemical synthesis methods across multiple industries
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
TWST Bull Case: What Could Go Right
- ✓
Consistent acceleration in core synthetic biology revenue growth
- ✓
Positive updates on DNA data storage pilots and commercialization timelines
- ✓
Demonstrated path to cash flow positivity or significant reduction in cash burn
- ✓
Expansion of key partnerships and customer agreements
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
